Key Points
- John Walter Hanna, Jr., CareDx CEO, sold 19,280 shares on Jan. 22 at an average price of $21.16 for about $407,965, leaving him with 597,405 shares—a 3.13% reduction in his stake.
- CareDx beat quarterly expectations with EPS of $0.28 versus $0.13 and revenue of $100.06 million (up 20.7% year‑over‑year), and reported strong profitability metrics (ROE 20.15%, net margin 19.65%).
- The stock trades near $20.42 with a market cap of roughly $1.05 billion, and analysts hold a consensus "Hold" rating with an average price target of $26.67 amid mixed buy/hold opinions.
CareDx, Inc. (NASDAQ:CDNA - Get Free Report) CEO John Walter Hanna, Jr. sold 19,280 shares of CareDx stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total value of $407,964.80. Following the sale, the chief executive officer directly owned 597,405 shares of the company's stock, valued at approximately $12,641,089.80. This represents a 3.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
CareDx Stock Performance
CareDx stock opened at $20.42 on Friday. The business's 50-day simple moving average is $18.92 and its two-hundred day simple moving average is $15.93. The company has a market cap of $1.05 billion, a PE ratio of 17.16 and a beta of 2.49. CareDx, Inc. has a fifty-two week low of $10.96 and a fifty-two week high of $25.55.
CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.15. The firm had revenue of $100.06 million during the quarter, compared to analysts' expectations of $95.25 million. CareDx had a return on equity of 20.15% and a net margin of 19.65%.The company's revenue for the quarter was up 20.7% compared to the same quarter last year. During the same period last year, the business posted ($0.14) earnings per share. As a group, analysts predict that CareDx, Inc. will post -0.9 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on CDNA shares. Zacks Research raised shares of CareDx from a "strong sell" rating to a "hold" rating in a report on Tuesday, November 18th. Wall Street Zen raised shares of CareDx from a "hold" rating to a "buy" rating in a report on Sunday, December 21st. BTIG Research increased their price target on CareDx from $22.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, November 6th. Weiss Ratings reiterated a "hold (c-)" rating on shares of CareDx in a research note on Monday, December 29th. Finally, Craig Hallum downgraded CareDx from a "buy" rating to a "hold" rating and set a $26.00 target price on the stock. in a research note on Tuesday, January 6th. Three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $26.67.
Read Our Latest Research Report on CareDx
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hood River Capital Management LLC grew its position in shares of CareDx by 11.5% during the 2nd quarter. Hood River Capital Management LLC now owns 1,765,981 shares of the company's stock valued at $34,507,000 after acquiring an additional 182,025 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in CareDx in the 2nd quarter worth about $352,000. Envestnet Asset Management Inc. boosted its position in CareDx by 17.7% during the second quarter. Envestnet Asset Management Inc. now owns 22,489 shares of the company's stock worth $439,000 after purchasing an additional 3,389 shares in the last quarter. Geode Capital Management LLC grew its holdings in CareDx by 3.4% in the second quarter. Geode Capital Management LLC now owns 1,323,497 shares of the company's stock valued at $25,864,000 after purchasing an additional 43,074 shares during the period. Finally, Zweig DiMenna Associates LLC purchased a new stake in shares of CareDx in the second quarter valued at approximately $4,428,000.
About CareDx
(
Get Free Report)
CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.
The company's core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
